Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study

• Main Authors: Jessica Cusato (Author), Lorenzo Bertani (Author), Miriam Antonucci (Author), Cristina Tomasello (Author), Gian Paolo Caviglia (Author), Simone Dibitetto (Author), Alessandro Massano (Author), Michela Mangia (Author), Jacopo Mula (Author), Linda Ceccarelli (Author), Francesco Costa (Author), Federico Zanzi (Author), Marco Astegiano (Author), Davide Giuseppe Ribaldone (Author), Antonio D'Avolio (Author)
• Format: Book
• Published: MDPI AG, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Adalimumab (ADA) is a human anti-tumor necrosis factor (TNF-α) monoclonal antibody used in inflammatory bowel diseases, such as Crohn's disease (CD). Vitamin-D (VD) is important for biological functions, such as the modulation of expression of genes encoding enzymes and transporters involved in...